アトピー性皮膚炎を有する3カ月から24カ月未満の参加者におけるタピナロフクリーム1%の安全性と有効性を検討する研究 (Adoring)
タピナロフクリーム1%のアトピー性皮膚炎を有する生後3か月から24か月未満の小児参加者における安全性および有効性を調査するための、無作為化二重盲検ビヒクル対照(第1期間)およびオープンラベル(第2期間)第3相試験
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35209
- AllerVie Clinical Research
-
-
Arkansas
-
Bryant、Arkansas、アメリカ、72022
- Dermatology Trial Associates
-
-
California
-
Los Angeles、California、アメリカ、90045
- Dermatology Research Associates
-
Sacramento、California、アメリカ、95815
- Integrative Skin Science and Research
-
San Diego、California、アメリカ、92123
- Allergy and Asthma Medical Group and Research Center
-
Thousand Oaks、California、アメリカ、91320
- Clinical Trials Research Institute
-
-
Colorado
-
Castle Rock、Colorado、アメリカ、80109
- Clarity Dermatology
-
-
Florida
-
Boca Raton、Florida、アメリカ、33486
- Skin Care Research, LLC.
-
Jacksonville、Florida、アメリカ、32256
- APEX Clinical Trials
-
Wellington、Florida、アメリカ、33449
- TruDerm Research
-
-
Georgia
-
Cumming、Georgia、アメリカ、30040
- Cleaver Medical Group Dermatology, Inc
-
-
Idaho
-
Meridian、Idaho、アメリカ、83646
- Ada West Research
-
-
Illinois
-
Skokie、Illinois、アメリカ、60077
- Endeavor Health Clinical Trials Center
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46250
- Dawes Fretzin Clinical Research Group, LLC
-
Plainfield、Indiana、アメリカ、46168
- The Indiana Clinical Trials Center, PC
-
-
Kentucky
-
Bowling Green、Kentucky、アメリカ、42104
- Equity Medical, LLC
-
-
Maryland
-
Rockville、Maryland、アメリカ、20850
- Lawrence J Green, MD LLC
-
-
Michigan
-
Auburn Hills、Michigan、アメリカ、48326
- Oakland Hills Dermatology
-
-
Minnesota
-
New Brighton、Minnesota、アメリカ、55112
- Minnesota Clinical Study Center
-
-
Mississippi
-
Ridgeland、Mississippi、アメリカ、39157
- SKY Integrative Medical Center
-
-
Missouri
-
Saint Joseph、Missouri、アメリカ、64506
- MediSearch Clinical Trials
-
-
Nevada
-
Reno、Nevada、アメリカ、89509
- Skin Cancer and Dermatology Institute
-
-
New York
-
Kew Gardens、New York、アメリカ、11415
- Forest Hills Dermatology Group
-
New York、New York、アメリカ、10012
- Bobby Buka MD, PC
-
The Bronx、New York、アメリカ、10455
- Equity Medical, LLC
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27516
- The University of North Carolina Dermatology and Skin Cancer Center
-
-
Ohio
-
Fairborn、Ohio、アメリカ、45324
- Dermatologists of Central States, LLC
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73120
- Allergy Asthma and Clinical Research Center
-
-
Oregon
-
Portland、Oregon、アメリカ、97210
- Oregon Dermatology and Research Center
-
Portland、Oregon、アメリカ、97239
- Oregon Health & Science University
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425
- Medical University of South Carolina
-
North Charleston、South Carolina、アメリカ、29420
- National Allergy and Asthma Research, LLC.
-
-
Texas
-
Bellaire、Texas、アメリカ、77401
- The University of Texas Health Science Center at Houston
-
Dallas、Texas、アメリカ、75230
- Dermatology Treatment and Research Center
-
Southlake、Texas、アメリカ、76092
- Stryde Research - Epiphany Dermatology
-
-
Washington
-
Spokane、Washington、アメリカ、99202
- Dermatology Specialists of Spokane
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2J 7E1
- Dermatology Research Institute
-
Red Deer、Alberta、カナダ、T4P 1K4
- CARe Clinic (Central Alberta Research Clinic)
-
-
British Columbia
-
Surrey、British Columbia、カナダ、V3R 6A7
- Dr. Chih-Ho Hong Medical Inc.
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ、R3J 0S9
- Manitoba Allergy Research Inc.
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ、B3K 5R3
- Maritime Dermatology
-
-
Ontario
-
Burlington、Ontario、カナダ、L7L 6W6
- Halton Pediatric Allergy
-
Hamilton、Ontario、カナダ、L8S 1G5
- Triple A Lab Inc.
-
Niagara Falls、Ontario、カナダ、L2H 1C4
- Allergy Research Canada Inc.
-
-
Saskatchewan
-
Regina、Saskatchewan、カナダ、S4V 1R9
- Dr. Rachel Asiniwasis Medical Professional Corporation
-
Saskatoon、Saskatchewan、カナダ、S7K 2C1
- Skinsense Medical Research
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
- Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
- Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
- Legal guardian or primary caregiver is able and willing to adhere to protocol requirements
Exclusion Criteria:
- Significant neurological disorder or history of seizure
- Know clinically significant cardiac rhythm or cardiac disorder
- History of sudden infant death in a sibling
- Clinically significant chromosome abnormality
- History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
- Diseases that could cause pruritic and/or sleep disruption
- Immunocompromised
- Current chronic or acute infection requiring treatment
- Use of prohibited medication(s) or procedure(s)
- Use of prohibited medications by breastfeeding mother if breastfeeding participant
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Tapinarof cream
Tapinarof cream, 1%, applied topically once daily |
Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.
他の名前:
|
|
プラセボコンパレーター:Vehicle cream
Vehicle cream is applied topically once daily for up to 8-weeks. |
Applied topically once daily to lesions on participant's skin during the Double-Blind period. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
時間枠:Baseline to the end of the Open-Label Period, up to 56 weeks.
|
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% [10 handprints], upper extremities = 20% [20 handprints], trunk (including axillae and groin) = 30% [30 handprints], lower extremities, including buttocks, = 40% [40 handprints]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
時間枠:Baseline to the end of the Open-Label Period, up to 56 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
時間枠:Baseline to the end of the Open-Label Period, up to 56 weeks.
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
時間枠:Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
時間枠:Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
時間枠:Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Lead Late-Stage Clinical Development、Organon and Co
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- OG0505-3104
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。